Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer

NCT03085992 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: FOLFOXIRI plus Bevacizumab
OTHER: Chemoradiotherapy plus Bevacizumab

Sponsor

Azienda Ospedaliero, Universitaria Pisana